About Junhemeng
Junhemeng was founded in 2020 and is based in Hangzhou, China. Recombinant protein drugs are developed by the company to address toxicity and metabolic diseases. Focus is placed on products with applications in medical aesthetics and metabolism, such as recombinant botulinum toxin and growth hormone. Operations center on biotechnology and pharmaceutical development within the healthcare sector.
- Headquarter Hangzhou, China
- SectorsHealthcare
- InvestorsHoshi Capital
& 1 more
Funding Insights of Junhemeng
- Total Rounds 1
- Investors Count 2
All 1 funding rounds of Junhemeng with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2022 | – | Series A | – | – |
2 investors in total: 2 institutional.
Investors in Junhemeng
Junhemeng has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Hoshi Capital and Guangdian Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment in technological innovation and life sciences is managed. | 2020 | hoshicapital.com | Hangzhou, China | |
Guangdian Capital is focused on consumer tech investments. | 2016 | guangdiancapital.com | Shenzhen, China |
Investor details for Junhemeng
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Junhemeng
2 dated milestones of Junhemeng across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Junhemeng is founded.
- Funding First funding round.
Similar companies to Junhemeng
10 companies that operate in the same segment as Junhemeng (Toxicology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutic solutions for food allergies are developed via antibody platforms. | 2019 | San Francisco, California, United States | USD 75 M | – | – | |
Therapeutics for substance use disorders, including opioid-related conditions, are developed. | 2020 | Oakland, California, United States | USD 70 M | – | – | |
Drug delivery solutions via single-walled carbon nanotubes are offered. | 2008 | Houston, Texas, United States | USD 2.5 M | USD 5.07 M | 9 | |
Non-invasive drug testing technology is developed using fingerprints. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 25.71 M | – | – | |
Provides toxicology, chemistry, and consultancy services for agrochemical industries. | 2020 | Vapi, Gujarat, India | – | – | – | |
Instruments for rapid human DNA identification are developed. | 2006 | Pleasanton, California, United States | USD 92.06 M | USD 22.5 B | 78 | |
Oral therapies for snake bite treatment are developed. | 2015 | Corte Madera, California, United States | USD 16.48 M | – | – | |
Quantitative urine drug testing is provided for patient monitoring. | 2011 | San Diego, California, United States | – | – | 358 | |
Point-of-care platforms for heavy metal toxicity diagnostics are developed. | 1968 | Billerica, Massachusetts, United States | USD 34 M | – | – | |
Real-time trace gas analysis solutions are delivered using SIFT-MS technology. | 2002 | Christchurch, New Zealand | USD 11.9 M | USD 23.52 M | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Junhemeng
Junhemeng was founded in 2020 and raised its 1st funding round 2 years after it was founded.
Junhemeng is headquartered in Hangzhou, China. It is registered at Hangzhou, Zhejiang, China.
Junhemeng was founded in 2020 and is based in Hangzhou, China. Recombinant protein drugs are developed by the company to address toxicity and metabolic diseases. Focus is placed on products with applications in medical aesthetics and metabolism, such as recombinant botulinum toxin and growth hormone. Operations center on biotechnology and pharmaceutical development within the healthcare sector.
Junhemeng has 2 investors. Key investors include Hoshi Capital, and Guangdian Capital.